J
Jamshid Shirani
Publications - 1
Citations - 353
Jamshid Shirani is an academic researcher. The author has contributed to research in topics: Randomized controlled trial & Cardiomyopathy. The author has an hindex of 1, co-authored 1 publications receiving 109 citations.
Papers
More filters
Journal ArticleDOI
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
Iacopo Olivotto,Artur Oreziak,Roberto Barriales-Villa,Theodore P. Abraham,Ahmad Masri,Pablo García-Pavía,Pablo García-Pavía,Sara Saberi,Neal K. Lakdawala,Matthew T. Wheeler,Anjali T. Owens,Milos Kubanek,Wojciech Wojakowski,Morten Kvistholm Jensen,Juan Ramón Gimeno-Blanes,Kia Afshar,Jonathan Myers,Jonathan Myers,Sheila M. Hegde,Scott D. Solomon,Amy J. Sehnert,David Zhang,Wanying Li,Mondira Bhattacharya,Jay M. Edelberg,Cynthia Burstein Waldman,Steven J. Lester,Andrew Wang,Carolyn Y. Ho,Daniel Jacoby,Jozef Bartunek,Antoine Bondue,Emeline Van Craenenbroeck,David Zemanek,Morten Søndergaard Jensen,Jens Mogensen,Jens Jakob Thune,Philippe Charron,Albert Hagège,Olivier Lairez,Jean Noël Trochu,Christoph Axthelm,Hans Dirk Duengen,Norbert Frey,Veselin Mitrovic,Michael Preusch,Jeanette Schulz-Menger,Tim Seidler,Michael Arad,Majdi Halabi,Amos Katz,Daniel Monakier,Offir Paz,Samuel Viskin,Donna R. Zwas,Hans-Peter Brunner-La Rocca,Michelle Michels,Dariusz Dudek,Zofia Oko-Sarnowska,Nuno Cardim,Helder Pereira,Pablo García Pavia,Juan Ramon Gimeno Blanes,Rafael Hidalgo Urbano,Luis Miguel Rincón Diaz,Perry M. Elliott,Zaheer Yousef,Theodore Abraham,Paulino Alvarez,Richard G. Bach,Richard C. Becker,Lubna Choudhury,David Fermin,John L. Jefferies,Christopher M. Kramer,Neal K. Lakdawala,Steven Lester,Ali J. Marian,Mathew S. Maurer,Sherif F. Nagueh,David R. Owens,Florian Rader,Mark V. Sherrid,Jamshid Shirani,John Symanski,Aslan T. Turer,Omar Wever-Pinzon,Timothy C. Wong,Mohamad H. Yamani +88 more
TL;DR: Treatment with mavacamten improved exercise capacity, LVOT obstruction, NYHA functional class, and health status in patients with obstructive hypertrophic cardiomyopathy and highlights the benefits of disease-specific treatment for this condition.